CMA vs NRXS
CMA (CMA) versus Neuraxis, Inc. (NRXS) — a side-by-side from cached financials, not a winner call.
CMA (CMA) common stock.
Neuraxis, Inc. (NRXS) is a biotechnology company listed on AMEX.
CMA does not have a complete income-statement cache yet.
Latest reported NRXS revenue for 2025-12-31 was $3.6M. Net income was -$7.8M. Revenue was up 32.9% from 2024-12-31 to 2025-12-31. NRXS currently screens at market cap $83.1M.
NRXS currently screens at market cap $83.1M.
Not investment advice. Open the CMA and NRXS stock pages for the full models.
Not investment advice.